Meta-analysis results of GLP1-RAs trials for stroke risk with different baseline characteristics across studies, those diabetic populations not at risk, or those not at risk for CKD or CVD are summarized in the Supplementary material (fixed and random effect models; Supplementary Figures S7, S8). Here, GLP1R is linked to chronic kidney disease.